Author + information
- Jae-Youn Moon,
- Yeong-Min Lim,
- Kim Sang Hoon,
- Woo-In Yang,
- Won-Jang Kim,
- Jung Hoon Sung,
- In Jai Kim,
- Sang-Wook Lim and
- Cha Dong-Hun
Background: There are no previous data concerning serial changes in neutrophil gelatinase-associated lipocalin (NGAL) levels in ST-segment elevation myocardial infarction (STEMI) patients before versus after primary percutaneous coronary intervention (pPCI). Therefore, the aim of the present study was to evaluate changes in NGAL levels before versus after pPCI in STEMI patients and to analyze its role as a prognostic tool to assess clinical outcome.
Methods: We identified 169 STEMI patients who underwent pPCI within 12 hours of symptom onset and had plasma NGAL measurements prior to (pre-NGAL) and 6 hours after (post-NGAL) pPCI. The primary end point was 30 day all cause mortality, including cardiac death, while the secondary endpoint was the change in NGAL levels from before to after pPCI.
Results: The mean pre-NGAL and post-NGAL levels were 109.2 ± 76.1 ng/mL and 93.3 ± 83.8 ng/mL, respectively. Thirty day mortality occurred in 12 (7.1%) patients. In terms of changes in serial NGAL levels, post-NGAL levels were decreased in 132 patients (79%). Patients with elevated post-NGAL levels showed increased mortality compared with patients with decreased post-NGAL levels (p = 0.005). Multivariate logistic regression analysis revealed both age (OR = 1.132, 95% CI 1.020-1.257; p = 0.020) and post-NGAL levels (OR = 1.026, 95% CI 1.003-1.049; p = 0.029) were significant independent risk factors for 30-day mortality.
Conclusions: In a large percentage of STEMI patients, plasma post-primary PCI NGAL levels were decreased compared with pre-primary PCI NGAL levels, even with the administration of potentially nephrotoxic contrast medium. For patients who underwent pPCI, NGAL levels after pPCI seemed to be superior to NGAL levels before the procedure for the prediction of 30 day mortality outcome.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Novel Developments in Acute Coronary Syndromes
Abstract Category: 15. Interventional Cardiology: ACS/AMI/Hemodynamics and Pharmacology
Presentation Number: 1194-160
- 2017 American College of Cardiology Foundation